DexCom (NASDAQ:DXCM) Director Bridgette Heller Sells 1,012 Shares

DexCom, Inc. (NASDAQ:DXCM) Director Bridgette Heller sold 1,012 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the transaction, the director directly owned 27,031 shares of the company’s stock, valued at approximately $1,569,690.17. The trade was a 3.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

DexCom Price Performance

NASDAQ:DXCM traded up $1.48 during trading hours on Wednesday, reaching $59.61. The stock had a trading volume of 6,844,335 shares, compared to its average volume of 4,567,267. The stock has a market capitalization of $23.25 billion, a PE ratio of 41.40, a PEG ratio of 1.43 and a beta of 1.40. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $93.25. The company has a 50 day moving average price of $68.12 and a two-hundred day moving average price of $77.39. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. The firm had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same period last year, the firm posted $0.45 earnings per share. DexCom has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DexCom

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DXCM. Andra AP fonden purchased a new position in shares of DexCom during the second quarter worth approximately $26,000. Twin Peaks Wealth Advisors LLC purchased a new position in DexCom during the 2nd quarter worth $26,000. SJS Investment Consulting Inc. lifted its holdings in shares of DexCom by 4,800.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after buying an additional 384 shares during the period. Zions Bancorporation National Association UT purchased a new position in DexCom during the 1st quarter valued at about $27,000. Finally, Financial Consulate Inc. bought a new stake in shares of DexCom in the 3rd quarter valued at about $29,000. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the topic of several recent research reports. William Blair upgraded shares of DexCom to a “strong-buy” rating in a research report on Thursday, July 31st. BTIG Research decreased their price objective on DexCom from $109.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. The Goldman Sachs Group dropped their target price on DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a report on Wednesday, October 1st. Stifel Nicolaus assumed coverage on DexCom in a report on Tuesday, October 21st. They set a “buy” rating and a $85.00 price target on the stock. Finally, Piper Sandler set a $75.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research note on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $87.62.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.